EPHB1 is the gene with the highest mutation frequency and is highly expressed in high-risk PRAD patients, whereas the knockdown of EPHB1 inhibited cell viability, proliferation, invasion, and antiapoptotic activity. Here, EPHB1 is linked to prostate adenocarcinoma.